JPWO2022216580A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022216580A5 JPWO2022216580A5 JP2023561333A JP2023561333A JPWO2022216580A5 JP WO2022216580 A5 JPWO2022216580 A5 JP WO2022216580A5 JP 2023561333 A JP2023561333 A JP 2023561333A JP 2023561333 A JP2023561333 A JP 2023561333A JP WO2022216580 A5 JPWO2022216580 A5 JP WO2022216580A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- pembrolizumab
- patient
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 55
- 229960002621 pembrolizumab Drugs 0.000 claims 33
- 206010028980 Neoplasm Diseases 0.000 claims 31
- 201000011510 cancer Diseases 0.000 claims 21
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 12
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 7
- 229960005079 pemetrexed Drugs 0.000 claims 7
- 208000013056 classic Hodgkin lymphoma Diseases 0.000 claims 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 6
- 229910052697 platinum Inorganic materials 0.000 claims 6
- 238000007920 subcutaneous administration Methods 0.000 claims 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 6
- 206010008342 Cervix carcinoma Diseases 0.000 claims 5
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 5
- 201000010881 cervical cancer Diseases 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 230000001394 metastastic effect Effects 0.000 claims 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 4
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims 4
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 claims 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 4
- 238000002512 chemotherapy Methods 0.000 claims 4
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 238000002347 injection Methods 0.000 claims 3
- 239000007924 injection Substances 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 230000000306 recurrent effect Effects 0.000 claims 3
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 3
- 208000023747 urothelial carcinoma Diseases 0.000 claims 3
- 208000037845 Cutaneous squamous cell carcinoma Diseases 0.000 claims 2
- 206010061818 Disease progression Diseases 0.000 claims 2
- 206010014733 Endometrial cancer Diseases 0.000 claims 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 208000032818 Microsatellite Instability Diseases 0.000 claims 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 239000012829 chemotherapy agent Substances 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 2
- 201000007492 gastroesophageal junction adenocarcinoma Diseases 0.000 claims 2
- 230000033607 mismatch repair Effects 0.000 claims 2
- 230000000869 mutational effect Effects 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229940071643 prefilled syringe Drugs 0.000 claims 2
- 201000010106 skin squamous cell carcinoma Diseases 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000009098 adjuvant therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229960000304 folic acid Drugs 0.000 claims 1
- 235000019152 folic acid Nutrition 0.000 claims 1
- 239000011724 folic acid Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 238000009092 lines of therapy Methods 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 238000009099 neoadjuvant therapy Methods 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims 1
- 239000011715 vitamin B12 Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163172299P | 2021-04-08 | 2021-04-08 | |
| US63/172,299 | 2021-04-08 | ||
| PCT/US2022/023250 WO2022216580A1 (en) | 2021-04-08 | 2022-04-04 | Methods for treating cancer with subcutaneous administration of anti-pd1 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513247A JP2024513247A (ja) | 2024-03-22 |
| JPWO2022216580A5 true JPWO2022216580A5 (US20070167479A1-20070719-C00034.png) | 2024-05-28 |
Family
ID=83546458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561333A Pending JP2024513247A (ja) | 2021-04-08 | 2022-04-04 | 抗ｐｄ－１抗体の皮下投与によるがんの治療方法 |
Country Status (17)
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3065836A1 (en) * | 2017-06-05 | 2018-12-13 | The Council Of The Queensland Institute Of Medical Research | Agents for cancer therapy or prophylaxis and uses therefor |
| BR112020015915A8 (pt) * | 2018-02-13 | 2023-01-31 | Merck Sharp & Dohme | Usos de um anticorpo anti-pd-1 e um anticorpo anti-ctla4 ou fragmentos de ligação ao antígeno dos mesmos, bem como kit para tratamento de um paciente com câncer |
| EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (MP-1) ANTIBODIES AND THEIR METHODS OF USE |
-
2022
- 2022-04-01 TW TW111112795A patent/TW202305009A/zh unknown
- 2022-04-04 PE PE2023002821A patent/PE20240051A1/es unknown
- 2022-04-04 JP JP2023561333A patent/JP2024513247A/ja active Pending
- 2022-04-04 CR CR20230473A patent/CR20230473A/es unknown
- 2022-04-04 CN CN202280033638.8A patent/CN117279952A/zh active Pending
- 2022-04-04 BR BR112023020867A patent/BR112023020867A2/pt unknown
- 2022-04-04 AU AU2022254960A patent/AU2022254960A1/en active Pending
- 2022-04-04 AR ARP220100836A patent/AR125296A1/es unknown
- 2022-04-04 EP EP22785209.2A patent/EP4320163A1/en active Pending
- 2022-04-04 CA CA3214617A patent/CA3214617A1/en active Pending
- 2022-04-04 WO PCT/US2022/023250 patent/WO2022216580A1/en active Application Filing
- 2022-04-04 IL IL307430A patent/IL307430A/en unknown
- 2022-04-04 MX MX2023011857A patent/MX2023011857A/es unknown
- 2022-04-04 KR KR1020237038583A patent/KR20230170029A/ko active Search and Examination
-
2023
- 2023-10-05 CO CONC2023/0013273A patent/CO2023013273A2/es unknown
- 2023-10-05 DO DO2023000216A patent/DOP2023000216A/es unknown
- 2023-10-06 EC ECSENADI202376276A patent/ECSP23076276A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200281921A1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| JP5765634B2 (ja) | 低酸素活性化型プロドラッグを用いるがんの処置 | |
| US20150231219A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| CA2554463C (en) | Anti-cancer therapies | |
| JP2019532051A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2011511072A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 | |
| JP2012506448A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2021510725A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| KR101848131B1 (ko) | 저용량 이리노테칸염산염 수화물을 함유하는 항종양제 | |
| CN110730663B (zh) | 阿帕替尼和c-Met抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| FI3463345T3 (fi) | Farmaseuttisia yhdistelmiä | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2003533485A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2018126829A (ru) | Применение производных хинолина для лечения рака пищевода, а также способ лечения, фармацевтическая композиция и набор с их использованием | |
| JP2020505425A5 (US20070167479A1-20070719-C00034.png) | ||
| CN113840608B (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JPWO2022216580A5 (US20070167479A1-20070719-C00034.png) | ||
| JP7311177B2 (ja) | Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用 | |
| EP3733202A1 (en) | Use of combined treatment of pd-1 antibody and apatinib for treating triple negative breast cancer | |
| CN111569078A (zh) | Sirt1抑制剂在vegfr抑制剂与免疫检查点抑制剂联用引起的副作用上的应用 | |
| JP2016521760A (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| IL307430A (en) | Methods for treating cancer with subcutaneous administration of ANTI-PD1 antibodies | |
| WO2019196620A1 (zh) | 喹唑啉类化合物与阿瓦斯汀在制备防止疾病的联合用药物中的用途 |
